enGene (ENGN) announced the appointment of three new members to its board. As the company begins to focus on preparing for planned regulatory filings and commercialization, the organization has promoted the following individuals: Matthew Boyd has been named chief regulatory officer, Jill Buck has been named chief development officer, and Katherine Chan has been appointed executive director, urology clinical lead. Boyd was previously senior VP, regulatory affairs, a role he has held since September 2024. Buck has been promoted to chief development officer from her role as senior VP, clinical development operations, which she has held since September 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene gets Regenerative Medicine Advanced Therapy designation for detalimogene
- Optimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements
- enGene price target lowered to $19 from $34 at Morgan Stanley
- enGene Holdings Reports Q2 2025 Financial Results
- enGene Holdings Approves 2025 Employee Stock Purchase Plan